8-K: Drugs Made In America II Secures $150K Bridge Loan, Eyes $1.4M Convertible Note Financing

Drugs Made In America Acquisition II Corp. secured a $150,000 bridge loan from Alpha Multi Family Office, part of a larger $1.4 million convertible note financing plan to support its business combination efforts.

Summary

• Drugs Made In America Acquisition II Corp. (the Company) issued an unsecured convertible note (the Bridge Note) for $150,000 to Alpha Multi Family Office (the Investor) on March 11, 2026.
• This Bridge Loan is the initial part of a contemplated $1,400,000 financing (the Convertible Notes Financing) pursuant to a Letter of Intent (LOI).
• The Bridge Note has a maturity date nine months from issuance, does not bear interest, and may be converted into shares of the combined entity at a 35% discount to market price upon the consummation of the Company's initial business combination.
• Proceeds from the Bridge Loan are intended for accounting expenses, audit expenses, and other expenses related to the Business Combination.
• The Company entered into the LOI with the Investor on March 5, 2026, which was amended on March 9, 2026, to set the aggregate financing amount at $1,400,000.
• The remaining $1,250,000 of the proposed convertible notes financing is subject to the negotiation and execution of a definitive convertible note purchase agreement.
• The Addendum contemplates that at least $400,000 in aggregate funding will be disbursed to the Company on or prior to March 30, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it secures immediate funding and outlines a path for further capital, crucial for a SPAC. However, the significant conversion discount introduces potential future dilution for existing shareholders, tempering the overall sentiment.

Positives

• Secured $150,000 in bridge financing to cover immediate operational and regulatory expenses, ensuring continued compliance and listing.
• Established a Letter of Intent for a larger $1.4 million convertible note financing, indicating progress towards securing necessary capital for a business combination.
• The financing supports the company's ability to maintain its NASDAQ listing and pursue a business combination, which is critical for a SPAC.

Negatives

• The convertible note allows conversion at a 35% discount to market price, potentially leading to significant dilution for existing shareholders upon business combination.
• The full $1.4 million financing is not yet definitive, with $1.25 million still subject to negotiation and execution of a definitive purchase agreement.
• The company is incurring debt to cover operational expenses, suggesting a reliance on external funding to sustain its SPAC activities.

Risks

• Failure to complete a business combination within the applicable timeframe could leave the Convertible Note outstanding, subject to repayment or conversion into alternative equity interests.
• The remaining $1,250,000 of the proposed financing is not guaranteed and depends on the negotiation and execution of a definitive convertible note purchase agreement.
• Potential significant dilution for existing shareholders if the convertible notes are exercised at a 35% discount to market price.
• Reliance on external financing to cover ongoing operational, accounting, and regulatory expenses, which could be challenging if further funding is not secured.

Future Outlook

The company intends to use the proceeds from the financing to facilitate its initial business combination and maintain its NASDAQ listing. The remaining $1,250,000 of the proposed convertible notes financing is subject to negotiation and execution of a definitive agreement, with an intent to finalize it during the current week. A minimum of $400,000 in aggregate funding is expected to be disbursed by March 30, 2026.

Management Comments

• The Company intends to use the proceeds of the Bridge Loan for accounting expenses, audit expenses and other expenses related to the Business Combination.

Industry Context

StockSavvy.ai notes that this financing is typical for Special Purpose Acquisition Companies (SPACs) like DMIIU as they approach the deadline for completing a business combination. Such bridge loans and convertible note financings are crucial for covering ongoing operational and regulatory costs while a target acquisition is being finalized, especially when the SPAC's trust account funds are restricted until a de-SPAC transaction.

Comparison to Industry Standards

• The 35% conversion discount is a significant incentive for the investor, potentially higher than typical PIPE (Private Investment in Public Equity) discounts seen in more robust market conditions, reflecting the urgency or perceived risk associated with SPACs nearing their business combination deadline.
• Compared to other SPACs struggling to find suitable targets or facing redemption pressures, securing this financing, even with a substantial discount, positions DMIIU to continue its search and operational activities, unlike some peers that liquidate due to insufficient funds.

Stakeholder Impact

• Shareholders: Potential dilution from the conversion of notes at a 35% discount. However, securing financing helps the company continue operations and pursue a business combination, which could ultimately benefit shareholders if successful.
• Creditors (Investor): Alpha Multi Family Office gains the right to convert debt into equity at a significant discount, providing a favorable risk-reward profile.

Next Steps

• Negotiation and execution of a definitive Convertible Note Purchase Agreement for the remaining $1,250,000 financing.
• Disbursement of at least $400,000 in aggregate funding to the Company by March 30, 2026.
• Completion of the Company's initial business combination (de-SPAC transaction).

Key Dates

Recommendation

While the financing provides necessary runway for the SPAC to pursue its business combination, the significant 35% conversion discount for the investor introduces substantial potential dilution for existing shareholders. This creates a mixed outlook, suggesting a 'hold' position until more clarity emerges on the business combination and its terms, balancing the positive of continued operations against the negative of future dilution.

Keywords

SPAC, convertible note, bridge financing, business combination, de-SPAC, NASDAQ, Alpha Multi Family Office, DMIIU, financing, dilution, SEC filing, 8-K